Pediatric Infection and Vaccine

  • 제18권1호
  • /
  • Pages.68-79
  • /
  • 2011
  • /
  • 2384-1079(pISSN)
  • /
  • 2384-1087(eISSN)
대한소아감염학회 (The Korean Society of Pediatric Infectious Diseases)
권호 표지

불활화 분할 인플루엔자 백신의 국내 시판 후 조사 연구

Post-marketing Surveillance Study of an Inactivated Split-Virion Influenza Vaccine in Korea

  • 투고 : 2011.04.18
  • 심사 : 2011.06.03
  • 발행 : 2011.06.25
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

목 적:본 시판 후 조사(NCT00750360)는 2002년부터 국내에서 사용 허가된 정제불활화 3가 분할 인플루엔자 백신의 안전성 및 반응원성을 평가하기 위하여 시행되었다. 방 법:생후 6개월 이상의 소아 및 성인 피험자 총 883명을 대상으로 평가대상 인플루엔자 백신을 1회 접종하였다. 이전에 인플루엔자에 감염되지 않았거나 인플루엔자 백신을 접종하지 않은 만 9세 미만의 소아의 경우에는 1회의 추가접종을 실시 하였다. 411명의 피험자가 일일 기록카드를 사용하여 안정성 정보를 기록하였으며 본 보고서에는 이들 피험자들로부터 수집된 자료가 포함되어 있다. 전신 및 투여부위에서의 명시된 이상반응 및 명시되지 않은 이상반응의 발생률을 기록하였다(백신접종 후 각각 4일 및 21일 동안 추적 관찰하였음). 또한 연구진행기간 전체에 걸쳐서 중대한 유해사례를 추적 관찰하여 기록하였다. 결 과 : 가장 흔하게 관찰된 전신 및 투여부위에서의 명시된 이상반응은 접종부위 통증(만 6세 미만의 소아: 12.6%, 만 6세 이상의 소아: 34.7%), 발열(만 6세 미만: 1.3%) 그리고 근육통(만 6세 이상: 13.9%) 이었다. 등급 3의 명시된 이상반응은 전체 피험자의 4.0% 이하에서 보고되었다. 한국식품의약품 안전청의 기준에 따라 백신과 인과관계가 없는 중대한 유해사례도 기록하였다. 결 론 : 평가대상 백신의 전 연령대에서의 확립된 면역원성 및 우수한 안정성, 반응원성 프로파일과 국내에서의 높은 접종률을 고려할 때, 본 백신을 국가예방접종사업에 포함시켜 모든 연령대에서 계절성 인플루엔자 예방 접종을 증진시키기 위한 후보백신으로 추천할 수 있을 것이다.

Purpose : This post-marketing surveillance study (NCT00750360) assessed the safety and reactogenicity of an inactivated, trivalent split-virion influenza vaccine licensed for use in the Korea since 2002. Methods : Eight hundred and eighty three subjects aged 6 months received a single dose of the ${\geq}$ vaccine; an additional dose was administered to those aged <9 years and unprimed with an influenza vaccine. Four hundred and eleven subjects used diary cards to record safety information; this report presents data from these subjects. Incidence of solicited local, general and unsolicited adverse events (4-days and 21-days post-vaccination follow-up periods, respectively) were recorded. Serious adverse events (SAEs) were recorded throughout the study period. Results : Injection site pain (subjects aged <6 years: 12.6% of subjects, ${\geq}$6 years: 34.7%), fever (<6 years: 1.3%) and myalgia (${\geq}$6 years: 13.9%) were the most frequently recorded solicited local and general adverse events. Grade 3 solicited adverse events were reported by ${\leq}$4.0% subjects. No vaccine-related SAEs were recorded (KFDA criteria). Conclusion : Considering the vaccine's well-established immunogenicity and its favourable safety and reactogenicity profile across all age groups and its high coverage rate in Korea, it may be recommended as a candidate to facilitate annual seasonal influenza vaccination for all ages as part of the Korean National Immunization Program.

키워드

참고문헌

  1. World Health Organization (WHO). Position Paper Influenza Vaccines. Wkly Epidemiol Rec 2005;80:277-88.
  2. World Health Organization (WHO). Influenza overview. Available: http://www.who.int/mediacentre/factsheets/2003/fs211/en/ Accessed: 18 May 2010.
  3. Rose GW, Cooper CL. $Fluarix^{TM}$, inactivated split-virus influenza vaccine. Expert Opin Biol Ther 2006;6:301-10. https://doi.org/10.1517/14712598.6.3.301
  4. Nichol KL. Efficacy and effectiveness of influenza vaccination. Vaccine 2008;26S:D17-22.
  5. Tilburt JC, Mueller PS, Ottenberg AL, Poland GA, Koenig BA. Facing the challenges of influenza in healthcare settings: The ethical rationale for mandatory seasonal influenza vaccination and its implications for future pandemics. Vaccine 2008;26S:D27-30.
  6. Fiore AE, Shay DK, Broder K, Iskander JK, Uyeki TM, Mootray G, et al. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009. MMWR Morb Mortal Wkly Rep 2009;58:RR8.
  7. Kim SH, Huh JH, Bae SY, Kim JS, Yoon SY, Lim CS, et al. Epidemiology of respiratory viral infection in 2004-2006. Korean J Lab Med 2006;26:351-7. https://doi.org/10.3343/kjlm.2006.26.5.351
  8. Kim MR, Lee HR, Lee GM. Epidemiology of acute viral respiratory tract infections in Korean children. J Infect 2000;41:152-8. https://doi.org/10.1053/jinf.2000.0715
  9. Kim YK, Nyambat BH, Hong YS, Lee CG, Lee JW, Kilgore PE. Burden of viral respiratory disease hospitalizations among children in a community of Seoul, Republic of Korea, 1995-2005. Scand J Infect Dis 2008;40:946-53. https://doi.org/10.1080/00365540802398937
  10. Chun BC, Woo HJ, Park SC. Preventive efficacy of influenza vaccination against to influenza-like illness among eldery. Korean J Epidemiol 1999;21:205-19.
  11. Lee HJ. Classification of vaccination and immunization schedule recommended by the Korean Pediatric Society, 2008. J Korean Med Assoc. 2008;51:104-9. https://doi.org/10.5124/jkma.2008.51.2.104
  12. Kee SY, Lee JS, Cheong HJ, Chun BC, Song JY, Choi WS, et al. Influenza vaccine coverage rates and perceptions on vaccination in South Korea. J Infect 2007;55:273-81. https://doi.org/10.1016/j.jinf.2007.04.354
  13. The Korean Pediatric Society. [Influenza]. In: Kang JH, ed. Immunization Guideline. 5th ed. Seoul: The Korean Pediatric Society; 2002:[136-54].
  14. Seo JJ, Kim MJ, Kim SH, Kee HY, Chung JK, Kim ES, et al. Characterization of respiratory viral infection in children in Gwangju. J Infect and Chemother 2008;40:218-29. https://doi.org/10.3947/ic.2008.40.4.218
  15. Lee JS, Shin KC, Na BK, Lee JY, Kang C, Kim JH, et al. Influenza surveillance in Korea: establishment and first results of an epidemiological and virological surveillance scheme. Epidemiol Infect 2007;135:1117-23.
  16. Nah SY, Park SE, Park JY, Lee HJ. Epidemiology of influenza virus over 8 years (1990-1998) in Seoul, Korea. Korean J Infect Dis 1999;31:210-6.
  17. Glezen WP, Denny FW. Epidemiology of acute lower respiratory disease in children. N Engl J Med 1973;288:498-505. https://doi.org/10.1056/NEJM197303082881005
  18. Treanor JJ, Campbell JD, Brady RC, Keitel WA, Drame M, Jain VK, et al. Rapid licensure of a new, inactivated influenza vaccine in the United States. Hum Vaccin 2005;1:239-44. https://doi.org/10.4161/hv.1.6.2376
  19. Hehme NW, Kunzel W, Petschke F, Turk G, Raderecht C, van Hoecke C, et al. Ten years of experience with the trivalent split-influenza vaccine, $Fluarix^{TM}$. Clin Drug Invest 2002;22:751-69. https://doi.org/10.2165/00044011-200222110-00004
  20. El Sahly HM, Keitel WA. Clinical data on $Fluarix^{TM}$: an inactivated split seasonal influenza vaccine. Expert Rev Vaccines 2008;7:713-9. https://doi.org/10.1586/14760584.7.6.713
  21. Zaman K, Roy E, Arifeen SE, Rahman M, Raqib R, Wilson E, et al. Effectiveness of maternal influenza immunization in mothers and infants. N Engl J Med 2008;359:1555-64. https://doi.org/10.1056/NEJMoa0708630
  22. Heckler R, Baillot A, Engelmann H, Neumeier E, Windorfer A. Cross-Protection against homologous drift variants of influenza A and B after vaccination with split vaccine. Intervirology 2007;50:58-62. https://doi.org/10.1159/000096314